Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 1
1982 4
1983 2
1984 2
1985 12
1986 21
1987 31
1988 38
1989 38
1990 32
1991 57
1992 27
1993 34
1994 42
1995 49
1996 58
1997 49
1998 63
1999 51
2000 71
2001 70
2002 71
2003 73
2004 79
2005 75
2006 91
2007 84
2008 57
2009 56
2010 59
2011 56
2012 61
2013 70
2014 54
2015 50
2016 68
2017 46
2018 47
2019 44
2020 45
2021 56
Text availability
Article attribute
Article type
Publication date

Search Results

1,874 results
Results by year
Filters applied: . Clear all
Page 1
Recent advances in understanding and managing resistant/refractory hypertension.
Doumas M, Imprialos KP, Kallistratos MS, Manolis AJ. Doumas M, et al. F1000Res. 2020 Mar 9;9:F1000 Faculty Rev-169. doi: 10.12688/f1000research.21669.1. eCollection 2020. F1000Res. 2020. PMID: 32201574 Free PMC article. Review.
During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological options for the management of such patients. The Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatmen …
During the past few years, several studies have been performed to identify efficient and safe pharmacological and non-pharmacological option …
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.
Buitenwerf E, Osinga TE, Timmers HJLM, Lenders JWM, Feelders RA, Eekhoff EMW, Haak HR, Corssmit EPM, Bisschop PHLT, Valk GD, Veldman RG, Dullaart RPF, Links TP, Voogd MF, Wietasch GJKG, Kerstens MN. Buitenwerf E, et al. J Clin Endocrinol Metab. 2020 Jul 1;105(7):2381-91. doi: 10.1210/clinem/dgz188. J Clin Endocrinol Metab. 2020. PMID: 31714582 Free PMC article. Clinical Trial.
RESULTS: Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group compared to 12.2% (5.3-20.2)] in the doxazosin group (P = .75, r = 0.03). The hemodynamic instability score was 38.0 (28.8-58.0) and …
RESULTS: Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group …
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. McConnell JD, et al. N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656. N Engl J Med. 2003. PMID: 14681504 Free article. Clinical Trial.
The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the nee …
The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater …
Doxazosin in the current treatment of hypertension.
Wykretowicz A, Guzik P, Wysocki H. Wykretowicz A, et al. Expert Opin Pharmacother. 2008 Mar;9(4):625-33. doi: 10.1517/14656566.9.4.625. Expert Opin Pharmacother. 2008. PMID: 18312163 Review.
Data extraction was based on articles reporting at least 15 or more patients treated with combination of doxazosin with other antihypertensive drugs. RESULTS/CONCLUSIONS: In these studies doxazosin in either standard or extended-release formulation was added as a se …
Data extraction was based on articles reporting at least 15 or more patients treated with combination of doxazosin with other antihyp …
After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2004 Sep;5(9):1957-64. doi: 10.1517/14656566.5.9.1957. Expert Opin Pharmacother. 2004. PMID: 15330733 Review.
Doxazosin is now being used to treat benign prostatic hyperplasia (BPH). ...The main side effects with doxazosin are those commonly associated with lowering blood pressure, although doxazosin lowers blood pressure to a lesser extent in normotensives than hype
Doxazosin is now being used to treat benign prostatic hyperplasia (BPH). ...The main side effects with doxazosin are those com
Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin.
van der Zee PA, de Boer A. van der Zee PA, et al. Neth J Med. 2014 May;72(4):190-201. Neth J Med. 2014. PMID: 24829175 Free article. Review.
Nowadays, some centres use phenoxybenzamine, while others use doxazosin. The purpose of this review is to analyse the current evidence of the benefits and risks of phenoxybenzamine and doxazosin in the preoperative treatment of pheochromocytoma. ...RESULTS: No rando …
Nowadays, some centres use phenoxybenzamine, while others use doxazosin. The purpose of this review is to analyse the current evidenc …
Doxazosin and congestive heart failure.
Sica DA. Sica DA. Congest Heart Fail. 2002 May-Jun;8(3):178-84. doi: 10.1111/j.1527-5299.2002.00939.x. Congest Heart Fail. 2002. PMID: 12045387 Free article. Review.
Doxazosin remains a commonly used antihypertensive medication, although its use has been tainted by recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ...This finding was largely driven by congestive heart failure
Doxazosin remains a commonly used antihypertensive medication, although its use has been tainted by recent findings from the Antihype
Pharmacologic expulsive treatment of ureteral calculi.
Beach MA, Mauro LS. Beach MA, et al. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1361-8. doi: 10.1345/aph.1G586. Epub 2006 Jul 18. Ann Pharmacother. 2006. PMID: 16849614 Review.
MeSH headings included ureteral calculi, nifedipine, doxazosin, and adrenergic alpha-antagonists. Key terms were ureteral calculi, nifedipine, tamsulosin, terazosin, and doxazosin. STUDY SELECTION AND DATA EXTRACTION: Trials evaluating nifedipine, tamsulosin, terazo …
MeSH headings included ureteral calculi, nifedipine, doxazosin, and adrenergic alpha-antagonists. Key terms were ureteral calculi, ni …
Photolytic and photocatalytic degradation of doxazosin in aqueous solution.
Bujak IT, Kralj MB, Kosyakov DS, Ul'yanovskii NV, Lebedev AT, Trebše P. Bujak IT, et al. Sci Total Environ. 2020 Oct 20;740:140131. doi: 10.1016/j.scitotenv.2020.140131. Epub 2020 Jun 12. Sci Total Environ. 2020. PMID: 32563879
Doxazosin (DOX), a selective alpha blocker, is widely used in medical therapy as an effective antihypertensive agent. ...In this study we focused on photolytic and TiO(2) photocatalytic degradation processes of doxazosin under different simulated conditions, with th
Doxazosin (DOX), a selective alpha blocker, is widely used in medical therapy as an effective antihypertensive agent. ...In this stud
[How effective is finasteride?].
Krome S. Krome S. Dtsch Med Wochenschr. 2011 Feb;136(8):354. doi: 10.1055/s-0031-1275154. Epub 2011 Feb 23. Dtsch Med Wochenschr. 2011. PMID: 21348003 Review. German. No abstract available.
1,874 results